Oncology

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

The gene-editing technology has been used successfully in a pediatric patient with T-cell ALL.

As psychedelic medicine comes further into cancer care, pharmacists will be an important part of the interdisciplinary team in screening and evaluating patients for suitability for psychedelic medicine.

A panel of experts discuss how to define traditional vs nontraditional careers in oncology pharmacy.

In a phase 3 trial, the risk of disease progression, relapse, or death was reduced by 27% with polatuzumab vedotin-piiq plus R-CHP compared with R-CHOP in adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

Mosunetuzumab-axgb may be better tolerated by older adults with relapsed or refractory follicular lymphoma and patients with poor performance status.

Omidubicel-onlv therapy aims to quicken the recovery of neutrophils and reduce the risk of infection in patients with cancer.

Durvalumab lowered the risk of death by 32% in patients with non-small cell lung cancer compared to chemotherapy alone.

Substantial strides have been made in the management of Ph+ ALL.

The treatment from Keytruda and Merck shows a clinical response of 89% for individuals with unresectable metastatic desmoplastic melanoma.

Multicancer early detection test could detect cancer with an AUC of 0.94 for all cancer types and stages.

According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.

Major pathologic response had a high association with increased recurrence-free survival rates.

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

These data support using this combination therapy as a new first-line treatment option in patients with previously untreated metastatic or unresectable BTC.

Based on the study results, investigators concluded that there is justification for a randomized clinical trial.

The Aquilino Cancer Center established the Bill Richards Center for Healing inside the same building, so patients with cancer can receive psychedelic-assisted therapy in the same location as their cancer care.

A standard chronological definition for older adults in oncology would be beneficial.

Remote services allow unrivaled opportunities for outreach to vulnerable populations and those in rural areas.

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

Individuals treated with the drugs from AstraZeneca demonstrate clinically meaningful and statistically significant improvement.

The overall survival hazard ratio numerically favored niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort in patients with platinum-sensitive recurrent ovarian cancer.

Brianna Hawkins, MBA, a University of Tennessee Health Science Center doctor of pharmacy candidate, discusses oncology drug development and how students can start a career in this alternative path.

It would also be beneficial to include a patient’s entire healthcare team in this management strategy, said an expert at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2023 in Phoenix, Arizona.

Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.

Consistent toxicity management and education reinforcement can improve the patient’s treatment management strategy.